A new artificial intelligence (AI) tool may help predict the structure of amyloid fibrils, that is, misfolded protein fibers that accumulate in the brain of people with neurodegenerative diseases such as Parkinson’s. Called Ribbonfold, the tool is designed to address the complex and variable structures of misfolded proteins by…
Researchers and students at the University of Wisconsin-La Crosse (UWL) are developing evidence-based occupational therapy practices to help people with Parkinson’s disease manage their condition and regain the ability to participate in the activities they enjoy. The research aims to help occupational therapy professionals deliver the best possible…
Photopharmics will use $6 million in newly secured funding to complete a Phase 3 clinical trial testing Celeste, its light therapy device for Parkinson’s disease, and to support precommercialization efforts before submitting regulatory applications. The ongoing Phase 3 trial (NCT04453033), dubbed Light for PD, has enrolled more…
Adults with Parkinson’s disease treated with the cell therapy bemdaneprocel spent less time in off periods, when symptoms were not adequately controlled despite medication use. That’s according to final published data from the exPDite Phase 1 trial (NCT04802733), which also showed that the cell therapy boosted the time…
The Parkinson Voice Project (PVP) has awarded a specialized training grant to the speech-language pathology program at Yeshiva University in New York that will enable graduate students to offer virtual SPEAK OUT! voice therapy to people living with Parkinson’s disease. SPEAK OUT! is a research-backed therapy program…
1ST Biotherapeutics said it joined an initiative led by the Michael J. Fox Foundation (MJFF) aimed at advancing therapies that target the LRRK2 gene, a key genetic contributor to Parkinson’s disease. The initiative, MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE) program, brings together biotech companies and academic research…
A case study of 10 people who experienced tics in childhood and developed Parkinson’s disease as adults illustrates how the underlying mechanisms of both disorders might be more complex than hypothesized. Researchers looked at individuals whose tics continued after the onset of Parkinson’s symptoms and treatment. Most…
Two undergraduate students from Rice University in Houston have designed an affordable, vibrating glove that they say lets patients feel vibrations in their fingertips to retrain misfiring neurons (nerve cells) in the brain — a hallmark of Parkinson’s disease — and help them regain motor control. The work by…
The U.S. Food and Drug Administration (FDA) has accepted an investigational new drug (IND) application for XS-411, a stem cell-based therapy developed by Xellsmart for Parkinson’s disease, clearing the way for a Phase 1 clinical trial. The company also received FDA approval for a similar stem cell therapy…
Nearly 1 in 8 people diagnosed with Parkinson’s disease in Finland within the past couple of decades were later given a different diagnosis, usually within two years, underscoring the need for better clinical criteria and regular checkups. When Parkinson’s and dementia with Lewy bodies, a neurodegenerative disease also…
Get regular updates to your inbox.
